0.04
-0.0056(-11.20%)
Currency In USD
| Previous Close | 0.05 |
| Open | 0.05 |
| Day High | 0.05 |
| Day Low | 0.04 |
| 52-Week High | 0.05 |
| 52-Week Low | 0.04 |
| Volume | 13,677 |
| Average Volume | 57,816.42 |
| Market Cap | 188,510 |
| PE | -0.03 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.04 |
| Moving Average 200 Days | 0.05 |
| Change | -0.01 |
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “Unboxing Biotech” Podcast KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- C
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Releas
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical c